229 related articles for article (PubMed ID: 27062540)
21. The number of risk factors is the strongest predictor of prostate cancer mortality: multi-institutional outcomes of an extreme-risk prostate cancer cohort.
Gomez-Iturriaga A; Cabeza Á; Pastor J; Jove J; Casaña M; Caamaño AG; Mengual J; Henríquez I; Muñoz J; Hervás A; Segundo CG
Clin Transl Oncol; 2016 Oct; 18(10):1026-33. PubMed ID: 26781470
[TBL] [Abstract][Full Text] [Related]
22. Expression of metallopanstimulin and oncogenesis in human prostatic carcinoma.
Fernandez-Pol JA; Fletcher JW; Hamilton PD; Klos DJ
Anticancer Res; 1997; 17(3A):1519-30. PubMed ID: 9179190
[TBL] [Abstract][Full Text] [Related]
23. Incidence of high chromogranin A serum levels in patients with non metastatic prostate adenocarcinoma.
Appetecchia M; Meçule A; Pasimeni G; Iannucci CV; De Carli P; Baldelli R; Barnabei A; Cigliana G; Sperduti I; Gallucci M
J Exp Clin Cancer Res; 2010 Dec; 29(1):166. PubMed ID: 21162758
[TBL] [Abstract][Full Text] [Related]
24. Low Serum Testosterone But Not Obesity Predicts High Gleason Score at Biopsy Diagnosed as Prostate Cancer in Patients with Serum PSA Lower than 20 ng/ml.
Shiota M; Takeuchi A; Sugimoto M; Dejima T; Kashiwagi E; Kiyoshima K; Inokuchi J; Tatsugami K; Yokomizo A
Anticancer Res; 2015 Nov; 35(11):6137-45. PubMed ID: 26504040
[TBL] [Abstract][Full Text] [Related]
25. Independent prognostic significance of HER-2 oncoprotein expression in pN0 prostate cancer undergoing curative radiotherapy.
Fosså A; Lilleby W; Fosså SD; Gaudernack G; Torlakovic G; Berner A
Int J Cancer; 2002 May; 99(1):100-5. PubMed ID: 11948499
[TBL] [Abstract][Full Text] [Related]
26. Stage at presentation and survival outcomes of patients with Gleason 8-10 prostate cancer and low prostate-specific antigen.
Falchook AD; Martin NE; Basak R; Smith AB; Milowsky MI; Chen RC
Urol Oncol; 2016 Mar; 34(3):119.e19-26. PubMed ID: 26526383
[TBL] [Abstract][Full Text] [Related]
27. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
[TBL] [Abstract][Full Text] [Related]
28. Compartmental Syndecan-1 (CD138) expression as a novel prognostic marker in triple-negative metaplastic breast cancer.
Ismail Y; Zakaria AS; Allam R; Götte M; Ibrahim SA; Hassan H
Pathol Res Pract; 2024 Jan; 253():154994. PubMed ID: 38071886
[TBL] [Abstract][Full Text] [Related]
29. Soluble Syndecan-1 Levels Are Associated with Survival in Platinum-Treated Bladder Cancer Patients.
Olah C; Tschirdewahn S; Hoffmann MJ; Krafft U; Hadaschik B; Nyirady P; Szendröi A; Módos O; Csizmarik A; Kovalszky I; Reis H; Szarvas T
Diagnostics (Basel); 2020 Oct; 10(11):. PubMed ID: 33114033
[TBL] [Abstract][Full Text] [Related]
30. Is there any prognostic impact of intraductal carcinoma of prostate in initial diagnosed aggressively metastatic prostate cancer?
Zhao T; Liao B; Yao J; Liu J; Huang R; Shen P; Peng Z; Gui H; Chen X; Zhang P; Zhu Y; Li X; Wei Q; Zhou Q; Zeng H; Chen N
Prostate; 2015 Feb; 75(3):225-32. PubMed ID: 25307858
[TBL] [Abstract][Full Text] [Related]
31. Syndecan-1 as a biomarker for sepsis survival after major abdominal surgery.
Holzmann MS; Winkler MS; Strunden MS; Izbicki JR; Schoen G; Greiwe G; Pinnschmidt HO; Poppe A; Saugel B; Daum G; Goetz AE; Heckel K
Biomark Med; 2018 Feb; 12(2):119-127. PubMed ID: 29327601
[TBL] [Abstract][Full Text] [Related]
32. Change in PSA velocity is a predictor of overall survival in men with biochemically-recurrent prostate cancer treated with nonhormonal agents: combined analysis of four phase-2 trials.
Suzman DL; Zhou XC; Zahurak ML; Lin J; Antonarakis ES
Prostate Cancer Prostatic Dis; 2015 Mar; 18(1):49-55. PubMed ID: 25384338
[TBL] [Abstract][Full Text] [Related]
33. Significance of preoperative butyrylcholinesterase as an independent predictor of biochemical recurrence-free survival in patients with prostate cancer treated with radical prostatectomy.
Koie T; Ohyama C; Hatakeyama S; Imai A; Yoneyama T; Hashimoto Y; Yoneyama T; Tobisawa Y; Hosogoe S; Yamamoto H; Kitayama M; Hirota K
Int J Clin Oncol; 2016 Apr; 21(2):379-383. PubMed ID: 26223693
[TBL] [Abstract][Full Text] [Related]
34. Syndecan-1 expression is associated with tumor size and EGFR expression in colorectal carcinoma: a clinicopathological study of 230 cases.
Kim SY; Choi EJ; Yun JA; Jung ES; Oh ST; Kim JG; Kang WK; Lee SH
Int J Med Sci; 2015; 12(2):92-9. PubMed ID: 25589885
[TBL] [Abstract][Full Text] [Related]
35. Diagnostic and prognostic value of tissue and circulating levels of Ephrin-A2 in prostate cancer.
Li S; Wu Z; Chen Y; Kang Z; Wang H; He P; Zhang X; Hu T; Zhang Q; Cai Y; Xu X; Guan M
Tumour Biol; 2016 Apr; 37(4):5365-74. PubMed ID: 26561474
[TBL] [Abstract][Full Text] [Related]
36. Prostate cancer and radiation therapy--the message conveyed by serum prostate-specific antigen.
Zagars GK; Pollack A; von Eschenbach AC
Int J Radiat Oncol Biol Phys; 1995 Aug; 33(1):23-35. PubMed ID: 7543892
[TBL] [Abstract][Full Text] [Related]
37. Prognostic value of tissue and circulating levels of IMP3 in prostate cancer.
Szarvas T; Tschirdewahn S; Niedworok C; Kramer G; Sevcenco S; Reis H; Shariat SF; Rübben H; vom Dorp F
Int J Cancer; 2014 Oct; 135(7):1596-604. PubMed ID: 24615121
[TBL] [Abstract][Full Text] [Related]
38. Posttreatment Prostate-Specific Antigen 6 Months After Radiation With Androgen Deprivation Therapy Predicts for Distant Metastasis-Free Survival and Prostate Cancer-Specific Mortality.
Naik M; Reddy CA; Stephans KL; Ciezki JP; Garcia J; Grivas P; Stephenson AJ; Klein EA; Tendulkar RD
Int J Radiat Oncol Biol Phys; 2016 Nov; 96(3):617-23. PubMed ID: 27681757
[TBL] [Abstract][Full Text] [Related]
39. Elevated levels of autophagy-related marker ULK1 and mitochondrion-associated autophagy inhibitor LRPPRC are associated with biochemical progression and overall survival after androgen deprivation therapy in patients with metastatic prostate cancer.
Zhang HY; Ma YD; Zhang Y; Cui J; Wang ZM
J Clin Pathol; 2017 May; 70(5):383-389. PubMed ID: 27679555
[TBL] [Abstract][Full Text] [Related]
40. Insulin-like growth factor 1, chromogranin A and prostate specific antigen serum levels in prostate cancer patients and controls.
Marszalek M; Wachter J; Ponholzer A; Leitha T; Rauchenwald M; Madersbacher S
Eur Urol; 2005 Jul; 48(1):34-9. PubMed ID: 15967249
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
